Physician profile
Young E Lee
NPI 1285833764
$4,960.33
in general payments reported to CMS, 2019-2025
34 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2021: $276 · 2022: $815 · 2023: $1,494 · 2024: $960 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $824.54 | 2019-2025 | Lifevest |
| Biotronik INC. | $675.50 | 2019-2023 | Amvia Edge, Biomonitor |
| Merck Sharp & Dohme LLC | $455.84 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $319.26 | 2022-2025 | |
| Pfizer INC. | $296.86 | 2022-2025 | |
| Abbott Laboratories | $252.08 | 2021-2025 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Amgen INC. | $168.50 | 2023-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.44 | 2023-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $154.83 | 2023-2025 | Assure Wcd |
| Braemar Manufacturing, LLC | $153.95 | 2019 | |
| Stryker Corporation | $149.29 | 2022 | |
| Boston Scientific Corporation | $145.63 | 2022-2023 | Watchman |
| E.R. Squibb & Sons, L.L.C. | $131.43 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $106.10 | 2021-2025 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $103.75 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $103.05 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $100.89 | 2021-2024 | Farxiga, Brilinta |
| Baxter Healthcare | $85.28 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Irhythm Technologies, INC. | $72.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $70.15 | 2019-2024 | |
| Abiomed | $57.58 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $44.48 | 2022-2023 | Arcalyst |
| Philips North America LLC | $43.81 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $36.43 | 2019 | |
| Esperion Therapeutics, INC. | $31.76 | 2023-2024 | Nexletol |
| Angiodynamics, INC. | $31.50 | 2023 | Angiovac |
| Teleflex LLC | $27.04 | 2025 | Guideliner |
| Novo Nordisk INC | $24.73 | 2024 | Ozempic, Rybelsus |
| Cardiva Medical, INC. | $24.71 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Lexicon Pharmaceuticals, INC. | $23.66 | 2023 | Inpefa |
| Chiesi USA, INC. | $21.36 | 2024 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $20.31 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.72 | 2024 | Arcalyst |
| Cvrx, INC. | $17.43 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.